Ocular Therapeutix (NASDAQ: OCUL) awards RSUs and options to CLO exec
Rhea-AI Filing Summary
Ocular Therapeutix Chief Legal Officer Todd Anderman reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units (RSUs), each representing one share of common stock, at a price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share and expiration on January 1, 2036. The option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date. After these transactions, he beneficially owned 152,468 shares of common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 197,650 | $0.00 | -- |
| Grant/Award | Common Stock | 64,900 | $0.00 | -- |
Footnotes (1)
- On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
